Condition: Rectal Cancer Patients · Sponsor: The Affiliated Hospital of Qingdao University
To evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the experimental combination of drugs CAPOX (Oxaliplatin and Capecitabine) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three years.
This description comes directly from the study's public registry record.
Yun Lu · 18661802231 · luyun@qdyy.cn
Yuan Gao · 18661806303 · gaoyuan@qdyy.cn
Always discuss trial participation with your own doctor first.
| The affiliated hospital of Qingdao university | Qingdao, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06647680